Crysvita Disease Interactions
There are 3 disease interactions with Crysvita (burosumab).
Burosumab (applies to Crysvita) hyperphosphatemia
Major Potential Hazard, Moderate plausibility. Applicable conditions: Phosphate Imbalance
Do not initiate burosumab-twza treatment if serum phosphorus is within or above the normal range for age. Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis. It is recommended to obtain baseline fasting serum phosphorus levels and to monitor fasting serum phosphorus levels. Dose interruption and/or dose reduction may be required based on a patient's serum phosphorus levels.
Burosumab (applies to Crysvita) renal impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction
Burosumab-twza is contraindicated in patients with severe renal impairment or end stage renal disease because these conditions are associated with abnormal mineral metabolism. The effect of renal impairment on the pharmacokinetics of burosumab-twza is unknown.
Burosumab (applies to Crysvita) RLS
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neurologic Disorder
The use of burosumab-twza may cause new onset of restless leg syndrome (RLS) or worsen RLS severity. Care should be exercised when using this agent in patients with existing RLS diagnosis.
Crysvita drug interactions
There are 16 drug interactions with Crysvita (burosumab).
More about Crysvita (burosumab)
- Crysvita consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.